Publication date: Oct 17, 2024
Through advocacy initiatives such as roadshows during “National ACP Week”, the Agency for Integrated Care (AIC) had increased advance care planning (ACP) engagement since 2011. Project Happy Apples (PHA), a community initiative project led by medical students from the National University of Singapore, also conducted a public exhibition to raise ACP awareness during this period. This study aimed to investigate and identify predictors of attitudes towards ACP documentation among ‘ACP Week’ respondents which may be used to formulate strategies to increase ACP documentation in Singapore. A cross-sectional study on ACP documentation attitudes of 262 respondents during local roadshows were conducted. Multiple logistic regression models were built to investigate the associations between demographic variables and attitudes toward ACP documentation. The mean age was 43. 5 years (SD = 17. 4), 79 (30. 15%) were males and 49 (18. 7%) were healthcare professionals (HCP). 117 (44. 66%) respondents had prior experience with serious illness and 116 (44. 27%) had heard of ACP. Age was a significant predictor of readiness to sign official papers naming nominated healthcare spokesperson (NHS) (OR = 1. 04, 95%CI: 1. 02-1. 07). Experience with serious illness was a significant predictor of readiness to discuss end-of-life (EOL) care with healthcare professionals (HCP) (OR = 3. 65, 95%CI: 1. 36-11. 61). Being female was a significant predictor for readiness to speak to their nominated healthcare spokesperson about EOL care (OR = 7. 33, 95%CI: 2. 06-46. 73). Subgroup analyses revealed that those aged 20-39 were less likely to speak to their healthcare professional about or sign official papers regarding EOL care. We also found that being a healthcare professional does not necessitate better or worse attitudes. Advocacy programs tailored to targeting respondents of different age groups and prior experience with serious illness may improve the efficacy of advocacy efforts.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | country |
| disease | MESH | end-of-life |
| drug | DRUGBANK | Tropicamide |
| pathway | REACTOME | Reproduction |
| disease | IDO | process |
| disease | MESH | COVID 19 |
| disease | MESH | marital status |
| drug | DRUGBANK | Zolmitriptan |
| drug | DRUGBANK | Iron |
| drug | DRUGBANK | Tretamine |
| disease | MESH | infection |
| drug | DRUGBANK | Indoleacetic acid |
| disease | MESH | aids |
| disease | MESH | confusion |
| disease | MESH | depression |
| disease | MESH | cancer |
| disease | MESH | Lung Cancer |
| drug | DRUGBANK | Dimethyl sulfone |
| disease | IDO | symptom |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | suicide |
| disease | MESH | anxiety |
| disease | IDO | intervention |